
News|Videos|August 1, 2024
Emerging Treatments in Mild/Moderate Multiple Sclerosis
Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).
Advertisement
Episodes in this series

BTK inhibitors: Do the current data suggest this strategy for mild MS?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
3
Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis
4
Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD
5






